451 related articles for article (PubMed ID: 14994125)
21. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
22. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
[TBL] [Abstract][Full Text] [Related]
23. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
24. Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation.
Esufali S; Bapat B
Oncogene; 2004 Oct; 23(50):8260-71. PubMed ID: 15377999
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
Hewitt SM; Hamada S; McDonnell TJ; Rauscher FJ; Saunders GF
Cancer Res; 1995 Nov; 55(22):5386-9. PubMed ID: 7585606
[TBL] [Abstract][Full Text] [Related]
26. Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.
Jilong Y; Jian W; Xiaoyan Z; Xiaoqiu L; Xiongzeng Z
Pathology; 2007 Jun; 39(3):319-25. PubMed ID: 17558858
[TBL] [Abstract][Full Text] [Related]
27. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
28. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors.
Amini Nik S; Hohenstein P; Jadidizadeh A; Van Dam K; Bastidas A; Berry RL; Patek CE; Van der Schueren B; Cassiman JJ; Tejpar S
Int J Cancer; 2005 Mar; 114(2):202-8. PubMed ID: 15540161
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor.
Fujimori M; Ikeda S; Shimizu Y; Okajima M; Asahara T
Cancer Res; 2001 Sep; 61(18):6656-9. PubMed ID: 11559529
[TBL] [Abstract][Full Text] [Related]
31. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours.
Sawyer EJ; Hanby AM; Rowan AJ; Gillett CE; Thomas RE; Poulsom R; Lakhani SR; Ellis IO; Ellis P; Tomlinson IP
J Pathol; 2002 Apr; 196(4):437-44. PubMed ID: 11920740
[TBL] [Abstract][Full Text] [Related]
32. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
33. Axin, the main component of the Wnt signaling pathway, is not mutated in kidney tumors in children.
Miao J; Kusafuka T; Udatsu Y; Okada A
Int J Mol Med; 2002 Apr; 9(4):377-9. PubMed ID: 11891531
[TBL] [Abstract][Full Text] [Related]
34. Myogenesis in Wilms tumors.
Sredni ST; Maschieto M; de Camargo B; Soares FA
Pediatr Dev Pathol; 2004; 7(6):668-9; author reply 670. PubMed ID: 15630541
[No Abstract] [Full Text] [Related]
35. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
Yun K; Fidler AE; Eccles MR; Reeve AE
Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
[TBL] [Abstract][Full Text] [Related]
37. beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.
Clements WM; Wang J; Sarnaik A; Kim OJ; MacDonald J; Fenoglio-Preiser C; Groden J; Lowy AM
Cancer Res; 2002 Jun; 62(12):3503-6. PubMed ID: 12067995
[TBL] [Abstract][Full Text] [Related]
38. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.
Chen YW; Jeng YM; Yeh SH; Chen PJ
Hepatology; 2002 Oct; 36(4 Pt 1):927-35. PubMed ID: 12297840
[TBL] [Abstract][Full Text] [Related]
39. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
40. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
